SAFETY, SIDE-EFFECTS AND PATIENT ACCEPTANCE OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE IN TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

被引:26
作者
ERI, LM
TVETER, KJ
机构
[1] Division of Urology, Department of Surgery, Ullevaal University Hospital, Oslo
关键词
ADVERSE EFFECTS; ANDROGEN ANTAGONISTS; PROSTATIC HYPERTROPHY; GONADORELIN;
D O I
10.1016/S0022-5347(17)32760-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia. Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks. Hemoglobin level decreased by 0.8 gm./100 ml. (p = 0.0052) for patients receiving leuprolide. Mean testicular volume decreased by 28.9% (p < 0.001) compared to placebo. Of 26 patients receiving leuprolide 5 had a weight gain of more than 3 kg. Almost all patients receiving leuprolide experienced hot flushes. Breast changes, and loss of energy and vigor were not more pronounced than for patients receiving placebo. Erectile function and sexual activity were lost during treatment. Libido also decreased but was still partially retained. Despite this, patients receiving leuprolide were generally contented with their sexual life during treatment. Side effects were bothersome for some patients but were reversible. Of the patients in our study 73% expressed that they could repeat or continue treatment if that had been possible. The high cost of these drugs will limit their use for a benign condition, such as benign prostatic hyperplasia.
引用
收藏
页码:448 / 452
页数:5
相关论文
共 27 条
[1]   PITUITARY AND TESTICULAR FUNCTIONS IN SEXUALLY MATURE RHESUS-MONKEYS UNDER HIGH-DOSE LRH-AGONIST TREATMENT [J].
AKHTAR, FB ;
WICKINGS, EJ ;
ZAIDI, P ;
NIESCHLAG, E .
ACTA ENDOCRINOLOGICA, 1982, 101 (01) :113-118
[2]   TREATMENT OF COMPLICATED BENIGN PROSTATIC HYPERPLASIA WITH LHRH-ANALOGUES IN AGED PATIENTS [J].
BIANCHI, S ;
GRAVINA, G ;
PODESTA, A ;
BARLETTA, D ;
FRANCHI, F ;
KICOVIC, P ;
LUISI, M .
INTERNATIONAL JOURNAL OF ANDROLOGY, 1989, 12 (02) :104-109
[3]   A COMPARISON OF ZOLADEX AND DES IN THE TREATMENT OF ADVANCED PROSTATE-CANCER - RESULTS OF A RANDOMIZED, MULTICENTER TRIAL [J].
CITRIN, DL ;
RESNICK, MI ;
GUINAN, P ;
ALBUSSAM, N ;
SCOTT, M ;
GAU, TC ;
KENNEALEY, GT .
PROSTATE, 1991, 18 (02) :139-146
[4]   EVIDENCE FOR TESTICULAR IMPAIRMENT AFTER LONG-TERM TREATMENT WITH A LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST IN ELDERLY MEN [J].
DECENSI, AU ;
GUARNERI, D ;
MARRONI, P ;
DICRISTINA, L ;
PAGANUZZI, M ;
BOCCARDO, F .
JOURNAL OF UROLOGY, 1989, 142 (05) :1235-1238
[5]   A PROSPECTIVE, PLACEBO-CONTROLLED STUDY OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE AS TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA [J].
ERI, LM ;
TVETER, KJ .
JOURNAL OF UROLOGY, 1993, 150 (02) :359-364
[6]  
ERI LM, 1992, EUR UROL, V22, P9
[7]   MEASUREMENT OF SKIN BLOOD-FLOW AND WATER EVAPORATION AS A MEANS OF OBJECTIVELY ASSESSING HOT FLUSHES AFTER ORCHIDECTOMY IN PATIENTS WITH PROSTATIC-CANCER [J].
FRODIN, T ;
ALUND, G ;
VARENHORST, E .
PROSTATE, 1985, 7 (02) :203-208
[8]   EFFECT OF A GNRH ANALOG (LEUPROLIDE) ON BENIGN PROSTATIC HYPERTROPHY [J].
GABRILOVE, JL ;
LEVINE, AC ;
KIRSCHENBAUM, A ;
DROLLER, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 64 (06) :1331-1333
[9]   EFFECT OF LONG-ACTING GONADOTROPIN-RELEASING HORMONE ANALOG (LEUPROLIDE) THERAPY ON PROSTATIC SIZE AND SYMPTOMS IN 15 MEN WITH BENIGN PROSTATIC HYPERTROPHY [J].
GABRILOVE, JL ;
LEVINE, AC ;
KIRSCHENBAUM, A ;
DROLLER, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 69 (03) :629-632
[10]  
GARNICK M, 1984, NEW ENGL J MED, V311, P281